---
title: "Entheon Biomedical Signs Definitive Agreement to Acquire Nutravisor"
description: "Entheon Biomedical Corp. has signed a definitive agreement to acquire Nutravisor Inc., merging the two businesses. Nutravisor will merge with a subsidiary of Entheon, leading to Entheon acquiring all "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273003905.md"
published_at: "2026-01-19T22:28:48.000Z"
---

# Entheon Biomedical Signs Definitive Agreement to Acquire Nutravisor

> Entheon Biomedical Corp. has signed a definitive agreement to acquire Nutravisor Inc., merging the two businesses. Nutravisor will merge with a subsidiary of Entheon, leading to Entheon acquiring all of Nutravisor’s shares in exchange for Entheon securities. The new company's board will include at least three directors, with Max Krangle as CEO. Further details will be disclosed later. This follows a prior letter of intent between the parties.

Entheon Biomedical Corp. has entered into a definitive agreement with Nutravisor Inc. to combine their businesses. Under the terms of the agreement, Nutravisor will merge with a wholly-owned subsidiary of Entheon, resulting in Entheon acquiring all of Nutravisor’s outstanding shares and securities in exchange for Entheon securities. Following the closing of the transaction, the resulting company’s board and executive team will include a minimum of three directors, with Max Krangle serving as Chief Executive Officer and Director. Further details about the management team and other aspects of the transaction will be provided in future disclosure documents. This agreement follows a previously announced letter of intent between the two parties. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entheon Biomedical Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 280858) on January 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [ENTA.US - Enanta Pharma](https://longbridge.com/en/quote/ENTA.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Enanta Pharmaceuticals: RSV Monoclonal Headwinds Turn Tailwind for Zelicapavir Treatment Opportunity | Enanta Pharmaceuticals received a Buy rating from analyst Brandon Folkes of H.C. Wainwright, with a price target of $20. | [Link](https://longbridge.com/en/news/276474081.md) |
| Breaking Down Ardelyx: 7 Analysts Share Their Views | In the latest quarter, 7 analysts provided mixed ratings for Ardelyx (NASDAQ:ARDX), with an average 12-month price targe | [Link](https://longbridge.com/en/news/276450068.md) |
| CSPC Pharmaceutical Group Limited Obtains Approval from the U.S. Food and Drug Administration to Conduct Clinical Trials in the U.S | CSPC Pharmaceutical Group Limited has received FDA approval to conduct clinical trials in the U.S. for its GLP-1/GIP rec | [Link](https://longbridge.com/en/news/276050786.md) |
| Merck Discloses Positive Data For Respiratory Syncytial Virus Antibody Treatment, Seeks FDA Nod For Broader Child Use | Merck & Co. has reported positive results from its Phase 3 SMART trial for the RSV treatment, Enflonsia, and is seeking  | [Link](https://longbridge.com/en/news/276335155.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/en/news/276037735.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.